Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
04 February 2022Website:
http://www.nuvectis.comNext earnings report:
08 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Mon, 04 Nov 2024 21:06:55 GMTDividend
Analysts recommendations
Institutional Ownership
NVCT Latest News
FORT LEE, N.J., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the third quarter of 2024 and provided an update on recent business progress.
The average of price targets set by Wall Street analysts indicates a potential upside of 229.3% in Nuvectis Pharma (NVCT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Fort Lee, NJ, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, will present at the following investor conferences:
The heavy selling pressure might have exhausted for Nuvectis Pharma, Inc. (NVCT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Fort Lee, NJ, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, will present at the 2023 Cantor Global Healthcare Conference Corporate Presentation, as follows:
Nuvectis is developing precision medicines for cancer patients, with lead asset NXP800 targeting ARID1a-mutated ovarian cancer. Preclinical trials have shown strong antitumor activity of NXP800, including in cisplatin resistant patients. NVCT also has a second asset, NXP900, which has shown significant single-agent activity in squamous cell cancer models.
Nuvectis Pharma, Inc. (NVCT) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
The average of price targets set by Wall Street analysts indicates a potential upside of 29.4% in Nuvectis Pharma, Inc. (NVCT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
FORT LEE, NJ, April 27, 2023 (GLOBE NEWSWIRE) -- In the news release, Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference, please note that the conference date is May 2nd, 2023. The complete, corrected release follows:
What type of business is Nuvectis Pharma?
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
What sector is Nuvectis Pharma in?
Nuvectis Pharma is in the Healthcare sector
What industry is Nuvectis Pharma in?
Nuvectis Pharma is in the Biotechnology industry
What country is Nuvectis Pharma from?
Nuvectis Pharma is headquartered in United States
When did Nuvectis Pharma go public?
Nuvectis Pharma initial public offering (IPO) was on 04 February 2022
What is Nuvectis Pharma website?
https://www.nuvectis.com
Is Nuvectis Pharma in the S&P 500?
No, Nuvectis Pharma is not included in the S&P 500 index
Is Nuvectis Pharma in the NASDAQ 100?
No, Nuvectis Pharma is not included in the NASDAQ 100 index
Is Nuvectis Pharma in the Dow Jones?
No, Nuvectis Pharma is not included in the Dow Jones index
When was Nuvectis Pharma the previous earnings report?
No data
When does Nuvectis Pharma earnings report?
The next expected earnings date for Nuvectis Pharma is 08 November 2024